Obesity Drug Warnings & FDA Approvals: What You Need to Know

Obesity Drug Warnings & FDA Approvals: What You Need to Know

January 14, 2026 Dr. Jennifer Chen Health

FDA Requests Removal of Suicide Risk Warnings for Weight Loss Drugs

The ⁢U.S. Food and Drug Governance​ asked manufacturers to remove warnings about a potential ⁤risk of suicidal thoughts from popular GLP-1 weight loss medications on January 13, 2026.This includes Novo Nordisk’s Wegovy ⁢and Eli ⁣Lilly’s Zepbound.

The request, as reported by Reuters, also extends to​ Novo Nordisk’s⁢ Saxenda. The FDA’s decision follows a review that found‌ no evidence linking​ GLP-1 receptor agonists to an increased risk ‍of suicidal⁤ thoughts⁢ or behavior.

These ⁢warnings were originally included​ as part of the drugs’ initial approval, ⁢based⁢ on reports of​ similar events observed with ‍older weight loss medications. removing the ‍warnings could alleviate⁣ a ⁣significant safety concern for this rapidly expanding ‍class of drugs.

Researchers are ‍currently⁤ testing or utilizing ⁢GLP-1⁤ medications⁤ for conditions beyond ⁣weight loss, including:

  • Cardiovascular issues
  • Fatty liver disease
  • Sleep ⁢apnea
,